Pubblicazioni

  • Home
  • Pubblicazioni
 
Assessing treatment response in pediatric multiple sclerosis patients
Giacomo Lus
Giacomo Lus
Vai all’articolo »
 
Do patients' and referral centers' characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register
Giacomo Lus
Giacomo Lus
Vai all’articolo »
 
Drivers of therapy switch in relapsing multiple sclerosis: a study from the Italian MS Registry
Giacomo Lus
Giacomo Lus
Vai all’articolo »
 
Exploring the reasons behind Ocrelizumab infusions delay during the first wave of COVID-19 pandemic in Italy: results of a survey among MS centers
Giacomo Lus
Giacomo Lus
Vai all’articolo »
 
Extended vs standard interval dose in Ocrelizumab treated MS patients during COVID-19 pandemic: an Italian experience
Giacomo Lus
Giacomo Lus
Vai all’articolo »
 
Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational study
Giacomo Lus
Giacomo Lus
Vai all’articolo »
 
Management of ocrelizumab in MS patients during the COVID-19 pandemic: an observational registry-based study
Giacomo Lus
Giacomo Lus
Vai all’articolo »
 
Ocrelizumab extended dosing in Primary Progressive Multiple Sclerosis during the COVID-19 pandemic: a multicenter experience
Giacomo Lus
Giacomo Lus
Vai all’articolo »
 
Predictors of cladribine effectiveness in multiple sclerosis: a real-world, multicenter, two-year follow-up study
Giacomo Lus
Giacomo Lus
Vai all’articolo »
 
Progression independent of relapse activity can occur in paediatric-onset multiple sclerosis and can be prevented by disease modifying drugs
Giacomo Lus
Giacomo Lus
Vai all’articolo »